Wuhan YZY Biopharma Co., Ltd., a biotechnology company, develops bispecific antibody-based therapies for the treatment of cancer, cancer-associated complications, and age-related ophthalmologic diseases. It develops various product candidates for the treatment of malignant ascites, malignant pleural effusion, solid tumors, pancreatic cancer, hepatocellular carcinoma, and other advanced solid tumors; wAMD, DME, and other ocular neovascularization-related diseases; hemophilia; and inflammatory bowel diseases. The company was founded in 2010 and is headquartered in Wuhan, China.
Frequently asked questions
What sector does Wuhan YZY Biopharma Co Ltd (2496) operate in?
Wuhan YZY Biopharma Co Ltd belongs to the Other sector and operates in the Biotechnology industry.
What is Wuhan YZY Biopharma Co Ltd (2496) current stock price?
As of the latest data, Wuhan YZY Biopharma Co Ltd stock price is HK$3.30, with a previous close of HK$3.30.
What is Wuhan YZY Biopharma Co Ltd (2496) current market capitalization?
Wuhan YZY Biopharma Co Ltd market cap is approximately 592.28 million.
What is Wuhan YZY Biopharma Co Ltd (2496) EBITDA?
Wuhan YZY Biopharma Co Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -3.71 million.
Does Wuhan YZY Biopharma Co Ltd (2496) pay dividends?
No. Wuhan YZY Biopharma Co Ltd does not pay a dividend.
What is Wuhan YZY Biopharma Co Ltd (2496) beta (volatility) score?
Wuhan YZY Biopharma Co Ltd has a beta of 0.491, indicating lower volatility than the overall market.
